Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AssigneeFive Prime Therapeutics, Inc.
InventorsSusannah D. BARBEE, Shujun YUAN, Marcel MEURY, Alessandro PALUMBO, Terence WONG, Kathrin ZUBERBUHLER, Emilia FALKOWSKA
Life of this patent
Estimating the term…
Abstract
This present invention provides anti-C—C chemokine type 8 (CCR8) antibodies and antigen binding fragments thereof, methods of making the antibodies or antigen binding fragments thereof, and methods of use thereof to bind to human CCR8 on CCR8 expressing cells, e.g., tumor-infiltrating Treg cells, to remove CCR8 expressing cells, e.g, tumor-infiltrating Treg cells, to reduce or inhibit tumor growth and/or to treat cancer.
Claims21
1-82. (canceled)
An antibody, or antigen-binding fragment thereof, that binds to C—C Chemokine Receptor 8 (CCR8), wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain variable region comprising:
- a CDR1 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 9, 15, 21, and 27;
- a CDR2 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 10, 16, and 28;
- and a CDR3 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 11, 17, 23, and 29;
- and
- (ii) a light chain variable region comprising:
- a CDR1 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 12, 30, and 42;
- a CDR2 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 13, 31, and 37;
- and a CDR3 domain comprising an amino acid sequence selected from a group consisting of SEQ ID NOs:
- 14, 20, and 32.
A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of claim 1, and a pharmaceutically acceptable carrier.
A polynucleotide comprising a polynucleotide encoding a polypeptide comprising:
- (a) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
- 76, and wherein the light chain when paired with a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 74 binds to CCR8;
- (b) an immunoglobulin light chain comprising the amino acid sequence set forth in SEQ ID NO:
- 76, and wherein the light chain when paired with a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 75 binds to CCR8;
- (c) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 74, and wherein the heavy chain when paired with a light chain comprising the amino acid sequence set forth in SEQ ID NO:
- 76 binds to CCR8;
- or
- (d) an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 75, and wherein the heavy chain when paired with a light chain comprising the amino acid sequence set forth in SEQ ID NO:
- 76 binds to CCR8.
Dependencies are inferred from the claim text.